Establishment Labs (NASDAQ: ESTA - Get Free Report) and Pediatrix Medical Group (NYSE: MD - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends. Profitability This table compares Establishment Labs and

Co-Diagnostics (NASDAQ: CODX - Get Free Report) and Establishment Labs (NASDAQ: ESTA - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Analyst Recommendations This is a summary of current ratings

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in TD Cowen's 46th Annual Health Care Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Monday, March 2, 2026 at 9:10 a.m. ET. A live webcast of the presentat.

In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profitability) and short-term price momentum-oriented stocks outperformed. Exact Sciences Corporation received a buyout offer in the fourth quarter by Abbott Laboratories (ABT) for a price of $105 in cash.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, February 24, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S.

Establishment Labs (NASDAQ: ESTA - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk. Valuation and Earnings This table compares Establishment Labs

Establishment Labs is transitioning to positive cash flow, ending its cash burn era and justifying its premium valuation. ESTA achieved 20% U.S. breast augmentation market share in under 18 months, outpacing historical competitors and establishing a robust commercial platform. Expansion into the reconstruction segment and minimally invasive procedures is set to double ESTA's addressable market and drive at least 25% annual revenue growth through 2027.

Establishment Labs Holdings Inc. (ESTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited financial results for the three months and fiscal year ended December 31, 2025. Establishment Labs' preliminary unaudited revenue for the fourth quarter of 2025 is expected to be in the range of $64.0 million to $65.0 million, including $17.0 m.

Establishment Labs (NASDAQ: ESTA - Get Free Report) and Tauriga Sciences (OTCMKTS:TAUG - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability. Valuation and Earnings This table compares Establishment Labs